Teleflex (NYSE:TFX) Reaches New 52-Week Low - Should You Sell?

Teleflex Incorporated (NYSE:TFX - Get Free Report)'s share price reached a new 52-week low during trading on Monday . The stock traded as low as $114.50 and last traded at $115.22, with a volume of 114432 shares trading hands. The stock had previously closed at $116.40.

Analyst Ratings Changes

Several research firms have recently commented on TFX. Wells Fargo & Company decreased their target price on Teleflex from $146.00 to $137.00 and set an "equal weight" rating on the stock in a research report on Friday, May 2nd. Truist Financial decreased their target price on Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a research report on Monday, May 5th. Mizuho set a $155.00 target price on Teleflex in a research report on Wednesday, April 16th. Morgan Stanley decreased their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research report on Monday, May 5th. Finally, Wall Street Zen downgraded Teleflex from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $164.63.

Teleflex Stock Down 0.5%

The firm has a 50 day simple moving average of $121.57 and a two-hundred day simple moving average of $142.82. The stock has a market capitalization of $5.12 billion, a P/E ratio of 36.52, a PEG ratio of 1.82 and a beta of 1.08. The company has a quick ratio of 1.32, a current ratio of 2.28 and a debt-to-equity ratio of 0.44.

Teleflex (NYSE:TFX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.91 earnings per share for the quarter, beating analysts' consensus estimates of $2.88 by $0.03. The firm had revenue of $700.67 million for the quarter, compared to the consensus estimate of $699.37 million. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. The company's revenue was down 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $3.21 EPS. On average, equities research analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 16th. Shareholders of record on Tuesday, May 20th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date was Tuesday, May 20th. Teleflex's dividend payout ratio is presently 42.90%.

Institutional Investors Weigh In On Teleflex

A number of large investors have recently modified their holdings of TFX. Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Teleflex by 242.9% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company's stock valued at $26,000 after acquiring an additional 153 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Teleflex by 103.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 100 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in shares of Teleflex in the 1st quarter valued at $27,000. Costello Asset Management INC bought a new position in shares of Teleflex in the 1st quarter valued at $28,000. Finally, Headlands Technologies LLC bought a new position in shares of Teleflex in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.